We evaluated the prediction of subsequent adverse events in a new @-group LVH classification based on LV dilatation ( high LV end-diastolic volume -LSB- EDV -RSB- index ) and concentricity ( mass/end-diastolic volume -LSB- M/EDV -RSB- ( @/@ ) ) in hypertensive patients .